Working… Menu
Trial record 5 of 232 for:    clindamycin

Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01722708
Recruitment Status : Recruiting
First Posted : November 7, 2012
Last Update Posted : July 23, 2019
Information provided by (Responsible Party):
HaEmek Medical Center, Israel

Brief Summary:
Abnormal vaginal flora is a risk factor for preterm labor. Therefore, in high risk pregnancies for preterm labor the diagnosis and treatment of abnormal flora is indicated. Clindamycin and metronidazole given orally are both acceptable treatments in these cases. The purpose of this study is to compare the effectiveness of Clindamycin Vs metronidazole for the treatment of abnormal vaginal flora in high risk pregnancies. For this purpose, pregnant women who are considered high risk for preterm labor and were diagnosed with abnormal vaginal flora will be randomly treated either with clindamycin or metronidazole. Eradication of the abnormal flora and adverse effects will be monitored and compared

Condition or disease Intervention/treatment Phase
Abnormal Vaginal Flora Clindamycin Vs Metronidazole High Risk Pregnancies for Preterm Labor Drug: Clindamycin Drug: Metronidazole Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 230 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Actual Study Start Date : April 2012
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Arm Intervention/treatment
Experimental: clindamycin Drug: Clindamycin
Oral clindamycin 300 Milligrams*2/Day for a week

Experimental: metronidazole Drug: Metronidazole
Oral metronidazole 500 Milligrams*2/Day for a week

Primary Outcome Measures :
  1. To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora [ Time Frame: Primary outcome will be assessed by taking a vaginal culture sample a week after one-week antibacterial treatment ]

Secondary Outcome Measures :
  1. The prevalence of adverse effects [ Time Frame: During the antibacterial treatment which is 1 week of therapy ]
  2. The prevalence of late abortions and preterm deliveries [ Time Frame: From date of randomization until the date of delivery or abortion, assessed up to 28 weeks ]
  3. Assessing the correlation between Nugent score , physical examination and Ph indicators [ Time Frame: The outcome is assessed after the diagnosis of abnormal vaginal flora is made at 14-26 weeks of gestation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnant women at increased risk for preterm labor (preterm cervical effacement, preterm uterine contractions, twins pregnancy, vaginal bleeding, past preterm delivery)
  • Age above 18 years

Exclusion Criteria:

  • Known allergy to the tested antibiotics
  • Antibacterial treatment in the week before the vaginal culture was taken
  • preterm premature rupture of membranes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01722708

Layout table for location contacts
Contact: Zohar Nachum, MD 972-46495483

Layout table for location information
Departement of obstetric and gynecology, HaEmek medical center Recruiting
Afula, Israel
Departement of obstetric and gynecology, Poriya Medical Center Not yet recruiting
Tiberias, Israel
Contact: Enav Yefet   
Principal Investigator: Enav Yefet         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Layout table for investigator information
Principal Investigator: Zohar Nachum, MD Departement of obstetric and gynecology, HaEmek medical center, Afula, Israel

Layout table for additonal information
Responsible Party: HaEmek Medical Center, Israel Identifier: NCT01722708     History of Changes
Other Study ID Numbers: 0012-12-EMC
First Posted: November 7, 2012    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Keywords provided by HaEmek Medical Center, Israel:
Abnormal vaginal flora
clindamycin Vs metronidazole
High risk pregnancies for preterm labor
Preterm labor
Late abortion
bacterial vaginosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Clindamycin palmitate
Clindamycin phosphate
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Anti-Infective Agents
Anti-Bacterial Agents
Antiprotozoal Agents
Antiparasitic Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action